U.K. startup Lucida Medical has received the CE Mark for its artificial intelligence (AI) software that detects prostate cancer.
Lucida's Prostate Intelligence (PI) application analyzes MRI scans to find cancer more accurately. Now that the software has received the CE Mark, it can be deployed within the U.K.'s National Health Service and European healthcare systems.
Lucida is a spin-out from Cambridge University that was founded by Dr. Evis Sala. The company received a round of investment funding in March from XTX Ventures and Prostate Cancer Research.
